Phylogenetic lineages of tuberculosis isolates and their association with patient demographics in Tanzania

Beatrice Kemilembe Mutayoba1,2,*, Michael Hoelscher2, Norbert Heinrich2, Moses L. Joloba3,4, Eligius Lyamuya5, Andrew Martin Kilale6, Nyagosya Segere Range6, Bernard James Ngowi6,7, Nyanda Elias Ntinginya8, Saidi Mwinjuma Mfaume6, Amani Wilfred9, Basra Doulla9, Johnson Lyimo10, Riziki Kisonga10, Amri Kingalu9, Jupiter Marina Kabahita3, Ocung Guido3, Joel Kabugo3, Isa Adam3, Moses Luutu4, Maria Magdalene Namaganda4, Joanitah Namutebi3, George William Kasule3, Hasfah Nakato3, Henry Byabajungu3, Pius Lutaaya3, Kenneth Musisi3, Denis Oola3, Gerald Mboowa11 and Michel Pletschette2

Abstract

Background: Mycobacterium tuberculosis presents several lineages each with distinct characteristics of evolutionary status, transmissibility, drug resistance, host interaction, latency, and vaccine efficacy. Whole genome sequencing (WGS) has emerged as a new diagnostic tool to reliably inform the occurrence of phylogenetic lineages of Mycobacterium tuberculosis and examine their relationship with patient demographic characteristics and multidrug-resistance development.

Methods: 191 Mycobacterium tuberculosis isolates obtained from a 2017/2018 Tanzanian drug resistance survey were sequenced on the Illumina Miseq platform at Supranational Tuberculosis Reference Laboratory in Uganda. Obtained fast-q files were imported into tools for resistance profiling and lineage inference (Kvarq v0.12.2, Mykrobe v0.8.1 and TBprofiler v3.0.5). Additionally for phylogenetic tree construction, RaxML-NG v1.0.3(25) was used to generate a maximum likelihood phylogeny with 800 bootstrap replicates. The resulting trees were plotted, annotated and visualized using ggtree v2.0.4

Results: Most [172(90.0%)] of the isolates were from newly treated Pulmonary TB patients. Coinfection with HIV was observed in 33(17.3%) TB patients. Of the 191 isolates, 22(11.5%) were resistant to one or more commonly used first line anti-TB drugs (FLD), 9(4.7%) isolates were MDR-TB while 3(1.6%) were resistant to all the drugs. Of the 24 isolates with any resistance conferring mutations, 13(54.2%) and 10(41.6%) had mutations in genes associated with resistance to INH and RIF respectively. The findings also show four major lineages i.e. Lineage 3 [81 (42.4%)], followed by Lineage 4 [74 (38.7%)] the Lineage 1 [23 (12.0%)] and Lineages 2 [13 (6.8%)] circulating in Tanzania.

Conclusion: The findings in this study show that Lineage 3 is the most prevalent lineage in Tanzania whereas drug resistant mutations were more frequent among isolates that belonged to Lineage 4.

Keywords: Phylogenetic, Lineages, Mycobacterial isolates, Whole-genome sequencing, Tanzania

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
in new cases to be 2.1%. This low prevalence is however likely to be due to under reporting and lack of intensive access to drug resistance testing (DST) [1]. Phylogenetic analysis has been revolutionary in understanding the evolutionary development and diversification of pathogenic organisms and is useful in understanding their distribution. Seven major lineages of Mycobacterium tuberculosis (M. tuberculosis), have been globally documented each exhibiting distinct characteristics from another in terms of evolutionary status, transmissibility, drug resistance, host interaction, latency, and vaccine efficacy [2]. These major lineages have been further subdivided into sub-lineages for example lineage 2 (East Asian) and lineage 4 (Euro-American) comprise the Beijing and Haarlem genotypes respectively. These show variation in virulence and pathogenicity with high association for tuberculosis outbreaks and drug-resistance [3]. Understanding TB transmission is key in disease control and prevention and the later highly depends upon rapid case detection. Rapid case detection should incorporate timely accurate drug susceptibility testing (DST) of Mycobacterium tuberculosis (M. tuberculosis) isolates. Several testing methods have been endorsed by the World Health Organisation (WHO) to test and confirm M. tuberculosis, revealing its phenotypic and genotypic characteristics. The most widely used phenotypic method i.e., culture and drug susceptibility testing are notoriously challenging and require stringent biosafety requirements to obtain the actual diagnosis [4]. These conventional methods are slow for comprehensive understanding of the M. tuberculosis infections to administer appropriate treatment. The molecular methods which include line-probe assays (LPAs) and Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) tend to overcome some of these challenges but fall short on covering the entire genomic understanding of the M. tuberculosis strains [5]. New molecular diagnostic methods based on genomic DNA sequencing have increasingly expounded TB genomics characteristically describing phylogeny of M. tuberculosis [6]. These include IS6110-RFLP methodology necessitating Southern blotting, spoligotyping, mycobacterial interspersed repetitive and whole genome sequencing (WGS) [7–10]. These have greatly improved the understanding of detection of unsuspected transmission and discrimination between re-infection, relapse and phylogeographical variations of the M. tuberculosis [11, 12].

Tanzania ranks among the seven TB high burden countries worldwide [13] with a total of 75,845 cases notified and incidence of 253 per 100,000 in 2018. The regional distribution of the cases in the country ranks Dar es Salaam city as the major contributor of TB cases notification at 20% contribution of all cases [13] with the rest in other regions of Mwanza, Arusha, Geita, Dodoma, Manyara and Mbeya but less has been done to understand the phylogenetic distribution.

Worldwide, vast numbers of sequences of M. tuberculosis strains have been generated with several libraries of single nucleotide poly-morphisms (SNPs) and other variants generated for comparative purposes. The research in low- and middle-income countries where Tanzania falls still lags in this area and more work needs to be done to guide accurate clinical decisions and provide more evidence of the prevailing strains in the country. To comprehensively understand the phylogeographical variations in Tanzania, we performed WGS on the drug resistance survey (DRS) isolates sourced all around Tanzania. Findings from this work should inform intervention strategies and future MDR-TB monitoring tactics. The sequence data will also help to understand the genomic characteristics of M. tuberculosis isolates and their resistant mutations prevalent among pulmonary TB patients enrolled during the second national anti-TB drug resistance survey in Tanzania.

Methods
Study design, population and sampling
This was a cross sectional national drug resistance survey conducted from June 2017 to July 2018. A cluster sampling strategy was used and the unit of sampling was a diagnostic center that notified 8 and more smear positive cases in 2015. Based on this, a total of 45 clusters were selected and in each cluster, a total of 34 new smear positive pulmonary TB patients and all previously treated smear positive pulmonary TB cases diagnosed during the intake period for the survey were enrolled. Sputum samples were collected and forwarded to the Central TB Reference Laboratory (CTRL) in Dar es Salaam for smear microscopy, culture, strain identification and susceptibility testing following standard NTLP procedures. For WGS, a total of 627 culture positive isolates were shipped to the National TB Reference Laboratory/Supranational Tuberculosis Reference Laboratory- Uganda.

Sub-culture and DNA extraction for whole-genome sequencing
All isolates were sub-cultured on selective Middlebrook 7H11 agar (Becton and Dickson, USA), incubated at 37°C in a CO₂ incubator (Panasonic, Osaka, Japan) and monitored weekly for growth. Once sufficient bacterial colonies were observed, these were harvested into a 15 ml Falcon tube with 1.0 ml of sterile water, followed by a thirty-minute heat inactivation at 85°C. High quality genomic DNA was extracted using an in-house cetyltrimethylammonium bromide (CTAB) method previously described [14]. Integrity of the extracted DNA was assessed using the TapeStation 4150 (Agilent USA) with
the Agilent Genomic DNA ScreenTape and reagents. Purity of the bacterial DNA was assessed using the NanoDrop 2000c (ThermoFisher Scientific).

Library preparation and sequencing
Genomic libraries were prepared using the Illumina Nextera XT library preparation kit following manufacturer’s instructions [15]. Quality of the prepared libraries was assessed with the Agilent 4150 using the D1000 High sensitivity ScreenTape and reagents. Libraries were sequenced on the MiSeq (Illumina, San Diego, CA, USA) using the Illumina MiSeq V3 cartridge at the Supranational Tuberculosis Reference Laboratory in Uganda.

Bioinformatics analysis
Resistance and lineage determination
A total of 191 samples were sequenced. Quality of reads was assessed using FastQC [16] v0.11.8 and MultiQC [17] v1.0. Bad quality bases were trimmed off using Trimmomatic v0.39 [18]. Three tools for resistance profiling and lineage inference namely Kvarq [19] v0.12.2, Mykrobe [20] v0.8.1 and TBprofiler [21] v3.0.5 were run.

Phylogenetic tree construction
De-novo genome assembly of all samples was done using Unicycler v0.4.8[22]. The assembled genomes were then annotated using Prokka [23] to generate genomic feature files to be used as input for Roary v3.13.0 [24] which was then used to generate a core gene multiple sequence alignment. Using the GTR + G substitution model, a maximum likelihood phylogeny was constructed using RaxML-NG v1.0.3 [25] with 800 bootstrap replicates with H37Rv reference strain NC_000962.3 as the reference and Mycobacterium canettii NC_015848.1 as the out-group. The resulting trees were plotted, annotated and visualized using ggtree v2.0.4 [26].

Ethical considerations
The study was approved by the National Health Research Ethics Committee of Tanzania and the Department of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany. Written informed consent or assent was obtained from all participants.

Results
Demographic characteristics of TB patients from whom the isolates were collected
Of the 627 samples received at the NTRL-Uganda, 10 were rejected and only 617 were sub-cultured. Of these 265 (43%) yielded either no growth (negative), contaminated or NTM and could not be processed further for WGS. Of the 352 samples that yielded a positive TB culture, 191 (54%) were sequenced due to resource constraints. Of these, 133 (70.0%) were from male TB patients. The mean age (standard deviation) of the TB patients from whom the isolates were collected was 37.5 (±13.8) years. Most (107; 55.8%) of the TB patients were aged 25–44 years. Most [169 (88.0%)] of the isolates were from newly treated pulmonary TB patients. Coinfection with HIV was observed in 33 (17.3%) of the 191 TB patients. Of the 191 isolates, 22 (11.5%) were resistant to one or more commonly used first line anti-TB drugs (FLD). While 3 (1.6%) were resistant to all the drugs, 9 (4.7%) isolates were MDR-TB (Supplementary data Table 1).

Phylogenetic analysis
From the 191 M. tuberculosis isolates, four main lineages were identified at different frequencies (Table 1). The dominant lineage was Lineage 3 [81 (42.4%)], followed by Lineage 4 [74 (38.7%)], then Lineage 1 [23 (12.0%)] and Lineage 2 [13 (6.8%)] (Table 1). Lineage 3 was the most prevalent among isolates from previously treated TB cases 9 (47.4%) as compared to 72 (41.9%) among isolates from newly treated patients. Lineage 4 dominated 7 (36.8%) those previously treated as compared to 67 (39.0%) of the newly treated. Lineage 1 was reported in 2 (10.5%) of the previously treated as compared to 21 (12.1%) of the newly treated patients. Lineage 2 was isolated in 1 (5.3%) of the previously treated TB case while the newly treated patients harboured 12 (6.9%) of these isolates. Lineage 3 was the most prevalent in both HIV positive 15 (5.5%) and HIV negative 66 (41.8%). This was

| M. tuberculosis lineages | Total n (%) | History of TB, n (%) | HIV Status, n (%) |
|-------------------------|------------|----------------------|-------------------|
|                         | n (%)      | Previously treated   | Newly treated     | HIV positive | HIV negative |
| Lineage 2               | 13 (6.8)   | 1 (5.3)              | 12 (7.0)          | 1 (3.0)     | 12 (7.6)    |
| Lineage 3               | 81 (42.4)  | 9 (47.4)             | 72 (41.9)         | 15 (45.5)   | 66 (41.8)   |
| Lineage 1               | 23 (12.0)  | 2 (10.5)             | 21 (12.1)         | 2 (6.1)     | 21 (13.3)   |
| Lineage 4               | 74 (38.7)  | 7 (36.8)             | 67 (39.0)         | 15 (45.5)   | 59 (37.3)   |
| Total                   | 191        | 19 (10.0)            | 172 (90.0)        | 33 (17.3)   | 158 (82.7)  |
also the case for Lineage 4 with 59 (37.3%) isolates from HIV negative and 15 (45.5%) from HIV positive patients (Table 1).

**M. tuberculosis Lineages and their correlation with drug resistance conferring mutation**

While the Lineage 2 had 1 (7.7%) isolate that showed resistance to rifampicin and ethambutol, Lineage 3 had 7 (8.6%) isolates resistant to FLDs, out of which 3 (3.7%) were MDR-TB. For Lineage 1, out of the 23 isolates, 5 (21.7%) were resistant to FLDs and 2 (8.7%) were MDR-TB. Out of 74 isolates for Lineage 4, 9 (12.2%) were resistant to FLDs and 3 (4.1%) were MDR-TB (Table 2).

**Frequency of drug resistant mutations**

The most prevalent Isoniazid conferring mutation was katG.Ser315Thr [9 (37.5%)]. The inhA.Ser94Ala and fabG1 c.-15C>T, c.-8 T>A, CTG607CTA had 1 (4.2%) mutation each. All Isoniazid conferring mutations were classified as common with a high resistance level observed in fabG1 c.-15C>T and katG. Ser315Thr while the promoter regions of inhA.Ser94Ala, fabG1.CTG607CTA and fabG1 c.-8 T>A. All had a low detected resistance level (Table 3).

The most prevalent Rifampicin resistance-conferring mutation were rpoB.Gln432Glu and rpoB.Ser450Leu with each accounting for a total of 3 (12.5%), while the remaining mutations were as follows: rpoB.Ser441Gln was found twice (8.3%), rpoB.His445Asn 1 (4.2%), and rpoB.Leu430Pro as well only 1 (4.2%). Rifampicin resistance-conferring mutation rpoB.His445Asn and rpoB.Ser441Gln were classified as rare with an equally low observed resistance level, while rpoB.Gln432Glu, rpoB.Leu430Pro and rpoB.Ser450Leu were classified as commonly occurring mutation with a high resistance level observed (Table 3).

Resistance-conferring mutations to Ethambutol in the embCAB loci were found in 8 (33.3%) isolates, with embB.Met306Ile being the most prevalent in 4 (16.7%), followed by embB.Gln497Arg at 2 (8.4%) while embB.Asp1024Asn and embB.Leu359Ile each had 1 (4.2%) mutation prevalence. All Ethambutol driven mutations were classified as common with a high resistance level. Resistance to Pyrazinamide at the pncA locus was identified in 8 (33.3%) isolates and none with rpsA. The most prevalent Pyrazinamide resistance-conferring mutation pncA.Ala30Val and GAG331TAG with each accounting for 2 (8.4%), while the remaining mutations of pncA.Leu172Pro, pncA.Phe106Leu, pncA Thr160Ala, and pncA.E111S all had 1 (4.2%) mutation each. Resistance conferring mutation at pncA.Phe106Leu was classified as rare while pncA.Leu172Pro, pncA.Ala30Val, pncA.GAG331TAG, pncA Thr160Ala and pncA.E111 were considered common (Table 3).

For Streptomycin resistance, mutation in the rpsL.Lys88Met was reported at 4 (16.7%) and were more frequent followed by resistance-conferring mutation in rrs. Ser172Cys at 1 (4.2%) while mutations in the gidB promoter region of Pro93Leu accounted for 1 (4.2%). Resistance to Ethionamide due to mutations in fabG1 and inhA were found in 2 (8.3%) of the isolates. Resistance-conferring mutation at loci fabG1 c.-15C>T and inhA.Ser94Ala each Ser94Ala were each reported at 1 (4.2%). Mutations in the conserved quinolone resistance-determining region (QRDR) of gyrA at position Ala90Val at 1 (4.2%) as well as Asp94Gly at 1 (4.2%) and classified as common (Table 3 and Supplementary data Table 3).

**Discussion**

This study reports the existence of heterogeneity among MTBC lineages circulating in Tanzania. Central Asian Lineage (L3) was the most predominant followed by Euro American (L4), Indo-Oceanic (L1) and East-Asian [2] lineage respectively. This is contrary to an earlier study done in the same setting that reported L4 to be the more widely distributed lineage as compared to L3 [27]. Previous studies have also highlighted that the East Asian lineage has only been recently circulating within the African continent which is consistent to findings in this study [28]. Furthermore, L3 was reported to be widely distributing among the newly treated population in this study as compared to the population with a previous history of TB treatment which may be suggestive of a high TB

**Table 2** Anti-TB drug resistance stratified by M. tuberculosis lineages, N=191

| M. tuberculosis lineages | Total n | Anti-TB drugs resistance (row %) |
|-------------------------|---------|---------------------------------|
|                         |         | INH n (%) | RMP n (%) | EMB n (%) | PZA n (%) | MDR n (%) | RFLD\(^a\) n (%) |
| Lineage 2               | 13      | 0 (0)     | 1 (7.7)   | 1 (7.7)   | 0 (0)     | 1 (7.7)   | 1 (7.7)   |
| Lineage 3               | 81      | 4 (4.9)   | 5 (6.1)   | 2 (2.4)   | 0 (0)     | 3 (3.7)   | 7 (8.6)   |
| Lineage 1               | 23      | 3 (13.0)  | 1 (4.4)   | 1 (4.4)   | 1 (4.4)   | 2 (8.7)   | 5 (21.7)  |
| Lineage 4               | 74      | 6 (8.1)   | 3 (4.1)   | 4 (5.4)   | 7 (9.5)   | 3 (4.1)   | 9 (12.2)  |

\(^a\)RFLD\(^a\) Resistant to first line drugs, INH Isoniazid, RMP Rifampicin, EMB Ethambutol, PZA Pyrazinamide, MDR Multi-drug resistance
**Fig. 1** Phylogenetic tree showing association between *Mycobacterium tuberculosis* lineages and drug resistance
transmission pattern of the widely transmitting L3 in Tanzania.

In this study, we show that East Asian lineage and Euro American lineages were largely found in TB patients living with HIV. This is a rare finding in Tanzania since no previous study has demonstrated no such association between TB drug resistance and HIV infection [29, 30]. However, our findings are in line with the findings from a recent study conducted in Haiti that reported the same MTB lineages harbouring MDR-TB resistance patterns as well as the higher risk of MDR-TB infection in people living with HIV (PLHIV) [31].

Although previous treatment for TB is the strongest risk factor for development of DR-TB [32–35], treatment-naïve patients may also acquire drug resistance due to either transmission of resistant strains or spontaneous mutations. In our study we report strains resistant to some SLDs which are not being used to treat TB in Tanzania. However, similar findings were reported in a study conducted in India to determine the antimicrobial susceptibility to first-line and second line anti-TB drug resistance among newly diagnosed pulmonary TB (PTB) cases, primary multi-drug resistance (MDR) and extensively drug resistance (XDR) were reported [36]. Prevalence of primary drug resistance serves as an epidemiological indicator to assess the success of the national TB control programme. Based on these findings, there is a need to give emphasis on appropriate screening of TB cases, effective and rational use of second line drugs for newly diagnosed MDR-TB patients to prevent the emergence of pre-XDR/XDR-TB strains.

Resistance to anti-TB drugs in *M. tuberculosis* arises as a result of spontaneous gene mutations that reduce the bacterium’s susceptibility to the most commonly used anti-TB drugs [37]. Several previous studies have identified different genes that encode anti-TB drug targets and have briefly described different mechanisms of resistance both to RIF and INH [37, 38].

### Table 3 Frequency of drug resistance mutations, N = 24

| Drug       | Gene | Mutation | Resistant (n/N (%)) | Classification of the mutation | Resistance level |
|------------|------|----------|---------------------|-------------------------------|-----------------|
| Isoniazid  | fabG1| c.-15C>T  | 1/24 (4.2%)         | Common                        | High            |
|            | fabG1| CTG607CTA | 1/24 (4.2%)         | Common                        | Low             |
|            | fabG1| c.-8 T>A   | 1/24 (4.2%)         | Common                        | Low             |
|            | inhA | Ser94Ala  | 1/24 (4.2%)         | Common                        | Low             |
|            | katG | Ser315Thr | 9/24 (37.5%)        | Common                        | High            |
| Rifampicin | rpoB | Gln432Glu | 3/24 (12.5%)        | Common                        | High            |
|            | rpoB | His445Asn | 1/24 (4.2%)         | Rare                          | Low             |
|            | rpoB | Leu430Pro | 1/24 (4.2%)         | Common                        | High            |
|            | rpoB | Ser441Gln | 2/24 (8.3%)         | Rare                          | Low             |
|            | rpoB | Ser450Leu | 3/24 (12.5%)        | Common                        | High            |
| Ethambutol | embB | Asp1024Asn| 1/24 (4.2%)         | Common                        | High            |
|            | embB | Gln497Arg | 2/24 (8.4%)         | Common                        | High            |
|            | embB | Leu359Ile | 1/24 (4.2%)         | Common                        | High            |
|            | embB | Met306Ile | 4/24 (16.7%)        | Common                        | High            |
| Pyrazinamide| pncA | Ala30Val  | 2/24 (8.4%)         | Common                        | High            |
|            | pncA | E111S     | 1/24 (4.2%)         | Common                        | Low             |
|            | pncA | GAG331TAG  | 2/24 (8.4%)        | Common                        | High            |
|            | pncA | Leu172Pro | 1/24 (4.2%)         | Common                        | High            |
|            | pncA | Phe106Leu | 1/24 (4.2%)         | Rare                          | Low             |
|            | pncA | Thr160Ala | 1/24 (4.2%)         | Common                        | High            |
| Streptomycin| gid | Pro93Leu | 1/24 (4.2%)         | Common                        | -               |
|            | rpsL | Lys88Met | 4/24 (16.7%)        | Common                        | -               |
|            | rrs  | Ser172Cys | 1/24 (4.2%)         | Common                        | -               |
| Ethionamide| fabG | c.-15C>T  | 1/24 (4.2%)         | Common                        | -               |
|            | inhA | Ser94Ala  | 1/24 (4.2%)         | Common                        | -               |
| Fluoroquinolones | gyrA | Ala90Val | 1/24 (4.2%)         | Common (LEV, MOX CC) | -               |
|            | gyrA | Asp94Gly  | 1/24 (4.2%)         | Common                        | -               |

**Note:** Indicates missing information on classification
The genes can encode drug targets or drug metabolism mechanisms and influence the efficacy of anti-TB treatment [13, 39, 40]. INH resistance appears more complex and has been associated with multiple genes, most commonly katG and the promoter region of the inhA gene [27]. In the current study, we report that the most prevalent INH conferring mutation was KatG.Ser315Thr [9 (37.5%)]. Other studies have also shown that molecular diagnostic tests for INH resistance rely on detection of the ‘canonical’ mutations in codon 315 of katG and position 15 in the inhA promoter region. Also, many earlier studies have identified highly variable frequencies of these mutations, with katG315 mutations accounting for 42–95% and inhA–15 mutations accounting for 6–43% of phenotypic INH resistance [38, 40]. Reta and colleagues [27] found a prevalence of 95.8% for the katG315 mutation and 5.9% for the inhA promoter area mutation in patients with INH-resistant M. tuberculosis in a systematic evaluation of gene variants related with RIF and INH resistant M. tuberculosis in Ethiopia.

According to the World Health Organization (WHO), Next-Generation Sequencing is an important technique for drug-resistant tuberculosis (TB) (DR-TB) surveillance [41]. Whole Genome Sequencing offers more accurate and complete results for both first-line and second-line anti-TB medications, as well as useful insights into molecular epidemiology, such as phylogenetics, strain evolution, and transmission, than the traditional phenotypic drug susceptibility test (DST) [41]. Despite the fact that our study did not set out to compare the performance of conventional phenotypic DST and WGS, we found higher levels of MDR-TB and resistance to one or more commonly used first-line anti-TB drugs than those found in Tanzania’s first national anti-TB drug resistance survey and the main survey from which the current isolates were derived. Other studies (not including national anti-TB surveys) [7, 32] have found that WGS testing of anti-TB drugs has the potential to provide comprehensive resistance detection much faster, with improved turnaround times, allowing for prompt appropriate treatment and associated patient and health-care benefits. [33].

Our study was limited to a small sample size, therefore findings of the phylogenetic distribution and association between lineages with patient demographic characteristics and drug resistance patterns may not be representative of the entire country profile. Furthermore, unavailability of data from conventional phenotypic DST methods in this study still limits our current understanding of the comparison of such methods with next generation sequencing approaches such as WGS in this setting.

Conclusion
The findings in this study shows existence of M. tuberculosis strains resistant to some second line drugs which were not routinely used to treat TB in Tanzania. Lineage 3 was the most prevalent among previously treated TB cases and in TB patients living with HIV. Lineage 1 and 4 were found to be prevalent in cases that were resistant to first line anti-TB drugs. The use of next generation sequencing tools such as WGS at a national anti-TB drug resistance survey is recommended as it may improve the epidemiological findings for appropriate interventions.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12864-022-08791-3.

Additional file 1: Supplementary data Table 1. Socio demographics, clinical characteristics and drug resistance among study subjects N=191.

M. tuberculosis lineages and their correlation with anti-TB drug resistance, N=191. Supplementary data Table 2. Pattern of drug resistance mutations by phylogenetic lineages, N=24.

Acknowledgements
We acknowledge the support rendered to the Global Fund Round New Funding Model 2 for the financial support that enabled the enrolment of the study patients and collection of sputum samples which were later used as sources of the isolates for the current study. We sincerely acknowledge the NTRL through the East, Central & Southern Africa Health Community (ECSA-HC) project that financed the procurement of the MiSeq sequencing machine, supporting equipment and reagents that were used to run the samples. We also thank the Nurturing Genomics and Bioinformatics Research Capacity in Africa (BReCA) project, award number 1U2RTW010672-01 for the Bioinformatics training provided to Jupiter Marina Kabahita and Maria Magdalene Namaganda. We also acknowledge the Gilead research support provided to Jupiter Marina Kabahita via the Infectious Diseases Institute, Makerere University. Kabahita Jupiter Marina was also was supported by the Fogarty International Center of the National Institutes of Health, U.S. Department of State’s Office of the U.S. Global AIDS Coordinator and Health Diplomacy (S/GAC), and President’s Emergency Plan for AIDS Relief (PEPFAR) under Award Number 1R25TW012113. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would also like to acknowledge the technical support and assistance provided by Mr. Edgar Kigozi and Mr. Fred Ashaba to the team that carried out WGS.

Authors’ contributions
BKM AMK MH NH EL NSR BJN NEN SMM JL RK and MP: Contributed to the conception of the study. BKM AMK MLJ NH EL NSR BJN NEN SMM JL RK and MP: Contributed to the design of the work. BKM MLJ DO AW KM AK BD SMM AK JK IA HB GWK PL JMK OG JN HN ML MWN GM: Contributed to the acquisition and analysis of data. BKM MLJ AMK DO AW KM AK BD SMM AK JK IA HB GWK PL JMK OG JN HN ML MWN GM NH EL NSR BJN NEN SMM JL RK and MP: Contributed to the interpretation of data. BKM MLJ AMK DO AW KM AK BD SMM AK JK IA HB GWK PL JMK OG JN HN ML MWN GM NH EL NSR BJN NEN SMM JL RK and MP: Drafted the work and substantively revised it. BKM MLJ AMK DO AW KM AK BD SMM AK JK IA HB GWK PL JMK OG JN HN ML MWN GM NH EL NSR BJN NEN SMM JL RK and MP: Approved the submitted version. BKM MLJ AMK DO AW KM AK BD SMM AK JK IA HB GWK PL JMK OG JN HN ML MWN, FA EK GM NH EL NSR BJN NEN SMM JL RK and MP: Agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. The author(s) read and approved the final manuscript.
Authors' information
Not applicable.

Funding
This study was funded by the Global Fund Round New Funding Model 2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are available at the SRA under the study BioProject ID: PRJNA807440 and at the Zenodo open access repository https://doi.org/10.5281/zenodo.6271274

Declarations

Ethics approval and consent to participate
The main study was approved by the National Health Research Ethics Committee (NatHREC) of the Medical Research Coordinating Committee in Tanzania (Certificate No. NIMR/HQ/RB/Vol. IX/2341 of 7th November 2016) and the Center for Global Health (CGH) at the U.S. Centers for Disease Control and Prevention (CDC). It was reviewed in accordance with the U.S. CDC human research protection procedures and determined to be research. Written informed consent was obtained from all participants or their legal guardians; assent was also obtained from children aged 15–17 years from whom the source sputum samples were collected. All methods were performed in accordance with the national guidelines and regulations.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Preventive Services, Ministry of Health, Dodoma, Tanzania.
2 Department of Infectious Diseases and Tropical Medicine, Medical Center of the, University of Munich, Munich, Germany.
3 National Tuberculosis Reference Laboratory/Supranational Reference Laboratory, Luzira, Uganda.
4 Department of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda.
5 Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
6 Muhimbili Research Centre, National Institute for Medical Research (NIMR), Dar es Salaam, Tanzania.
7 University of Dar Es Salaam, Mbeya College of Health and Allied Sciences, Mbeya, Tanzania.
8 Mbeya Medical Research Centre, NIMR, Mbeya, Tanzania.
9 Central Tuberculosis Reference Laboratory, Ministry of Health, National TB and Leprosy Programme, Dar es Salaam, Tanzania.
10Department of Preventive Services, Ministry of Health, National Tuberculosis and Leprosy Programme, Dodoma, Tanzania.
11Africa Centres for Disease Control and Prevention, African Union Commission, Addis Ababa, Ethiopia.

Received: 9 February 2022 Accepted: 12 July 2022
Published online: 05 August 2022

References
1. Musa BM, Adamu AL, Galadanci NA, Zubby B, Odoh CN, Aliyu MH. Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2017;12(9): e0185105. https://doi.org/10.1371/journal.pone.0185105.
2. Jones RC, Harris LG, Morgan S, et al. Phylogenetic analysis of Mycobacterium tuberculosis strains in Wales by use of core genome multilocus sequence typing to analyze whole-genome sequencing data. J Clin Microbiol. 2019;57:e02025-e2118. https://doi.org/10.1128/JCM.02025-18.
3. Marais BJ, Victor TC, Hesseling AC, et al. Beijing and Haarlem genotypes of Mycobacterium tuberculosis strains in Wales by use of core genome multilocus sequence typing to analyze whole-genome sequencing data. J Clin Microbiol. 2019;57:e02025-e2118. https://doi.org/10.1128/JCM.02025-18.
4. Tania T, Sudarmono P, Kusumawati RL, et al. Whole-genome sequencing analysis of multidrug-resistant Mycobacterium tuberculosis from Java. Indonesia J Med Microbiol. 2020;69(7):1013–9. https://doi.org/10.1099/jmm.0.0081221.
5. Wilson ML. Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. Arch Pathol Lab Med. 2013 Jun;137(6): 812e9. PubMed PMID: 23721277.
6. Gygli SM, Keller PM, Ballif M, et al. Whole-genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;64(7):1013–9. https://doi.org/10.1128/AAC.02175-18.
7. Doyle RM, Burgess C, Williams R et al. Direct whole-genome sequencing of sputum accurately identifies drug-resistant mycobacterium tuberculosis faster than MGIT culture sequencing. J Clin Microbiol. 2018;56(8). https://doi.org/10.1128/JCM.00666-18. PMID: 29848567; PMCID: PMC6028781.
8. Supply P, Allix C, Lejean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of mycobacterium tuberculosis. J Clin Microbiol. 2007;44:4498–510. https://doi.org/10.1128/JCM.01392-06.
9. Cronin WA, Golub JE, Magder LS et al. Epidemiologic usefulness of sputum smears in tuberculosis screening at the point of care: a systematic review and meta-analysis. PLoS ONE. 2017;12(9): e0185105. https://doi.org/10.1371/journal.pone.0185105.
10. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York city – an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med. 1994;330:1710–6. https://doi.org/10.1056/NEJM199406163302403.
11. Lagou J, Couvin D, Arata L, et al. Analysis of mycobacterium tuberculosis genotypic lineage distribution in Chile and neighboring countries. PLoS ONE. 2016;11(8) https://doi.org/10.1371/journal.pone.0160434.
12. Couvin D, Rastogi N. The establishment of databases on circulating genotypes of Mycobacterium tuberculosis complex and web tools for an effective response to better monitor, understand and control the tuberculosis epidemic worldwide: EuroReference - Les Cahiers de la Référence, ANSES. 2014;2014(12):36–48. (pasteur-0295417)
13. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
14. Kigozi E, Kasule GW, Musisi K, Lukoye D, Kyobe S, Katabazi FA, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS ONE. 2018;13(5)e0198091. https://doi.org/10.1371/journal.pone.0198091.
15. Illumina. Nextera-xt-library-prep-reference-guide-15031942-05.pdf. Document # 15031942-v05 May 2019. [Online]. Available: https://support.illumina.com/content/dam/illumina-support/documents/diagnostics/chemistry_documentation/samplepreps_nextera-xt/nextera-xt-library-prep-reference-guide-15031942-05.pdf. Accessed: 21 Sep 2021.
16. Babraham Bioinformatics. FastQC A Quality Control tool for High-Throughput Sequence Data. https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed Sep 22, 2021).
17. Ewles P, Magnusson M, Lundin S, Kaller M. MultiQC. Summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047–8. https://doi.org/10.1093/bioinformatics/btw354.
18. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20. https://doi.org/10.1093/bioinformatics/btu170.
19. Steiner A, Stucki D, Coscellia M, Borrell S, Gagneux S. KvarQ: targeted and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019;11:41. https://doi.org/10.1186/s13073-019-0650-x.
20. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. PLOS
23. Prokka ST. Rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068–9. https://doi.org/10.1093/bioinformatics/btu153.

24. Page AJ, Cummins CA, Hunt M, et al. Rapid large-scale prokaryote pan-genome analysis. Bioinformatics. 2015;31(22):3691–3. https://doi.org/10.1093/bioinformatics/btv421.

25. Kozlov AM, Darnilla D, Flouri T, Morel B, Stamatakis A. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35(21):4453–5. https://doi.org/10.1093/bioinformatics/btz305.

26. Yu G, Smith DK, Zhu H, Guan Y, Lam TTY. ggtree: an R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods Ecol Evol. 2017;8(1):28–36. https://doi.org/10.1111/2041-210X.12628.

27. Vilchèze C, Wang F, Arai M, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med. 2006;12:1027–1029.

28. Reta MA, Aleemneeb B, Beletew BA, Fourre PB. Prevalence of drug resistance-conferring mutations associated with isoniazid and rifampicin-resistant Mycobacterium tuberculosis in Ethiopia: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2021;26:207–18. https://doi.org/10.1016/j.jgar.2021.06.009.

29. Kremer K, van Soolingen D, Frothingham R, et al. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol. 1999;37(8):2607–18.

30. Urmubyeyi AN, Gasana M, Basenga P, et al. Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis. 2007;11(2):189–94.

31. Chum HJ, O’Brien RJ, Chonde TM, Graf P, Rieder HL. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991–1993. AIDS. 1996;10:299–309. https://doi.org/10.1097/00002030-199603000-00009.

32. Votintseva AA, Bradley P, Pankhurst L, et al. Same-day diagnostic and surveillance data for tuberculosis via whole-genome sequencing of direct respiratory samples. J Clin Microbiol. 2017;55(5):1285–98. https://doi.org/10.1128/JCM.02483-16.

33. Zhang Y, Zhao R, Zhang Z, et al. Analysis of factors influencing multidrug-resistant tuberculosis and validation of whole-genome sequencing in children with drug-resistant tuberculosis. Infect Drug Resist. 2021;4(14):4375–93. https://doi.org/10.2147/IDR.S331890. PMID: 34729015; PMCID: PMC8554314.

34. Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC. Patients previously treated tuberculosis no longer neglected. Clin Infect Dis. 2020;12(2):12–9. https://doi.org/10.5897/JBR2020.0319.

35. Myneedu VP, Singh R, Khayyam RU, Sharma PP, Bhalla M, Behera D, Saini R. First and second line drug resistance among treatment naive pulmonary tuberculosis patients in a district under revised national tuberculosis control programme (RNTCP) in New Delhi. J Epidemiol Glob Health. 2015;5(4):365–73. https://doi.org/10.1016/j.jegh.2015.04.002 Epub 2015 May 2. PMID: 25944154; PMCID: PMC47320499.

36. Torres JN, Paul LV, Rodwell TC, et al. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect. 2015;4(7):e42. https://doi.org/10.1038/emi.2015.42.

37. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13:1320–30.

38. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015;10:e0119628. https://doi.org/10.1371/journal.pone.0119628.

39. Marahatta SB, Gautam S, Dhital S, et al. katzG (SER 315 THR) gene mutation in isoniazid-resistant Mycobacterium tuberculosis. Kathmandu Univ Med J. 2011;9:19–23. https://doi.org/10.3126/kumj.v9i1.6256.

40. World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.